Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Shifts Meridia Marketing Focus From Consumer To Physicians

Executive Summary

Abbott plans to move away from direct-to-consumer advertising for the anti-obesity agent Meridia (sibutramine) in favor of marketing aimed more directly at healthcare providers.

You may also be interested in...



Metabolic Syndrome Reimbursement Forecast: Outlook Remains Cloudy

In the near term, the best prospect for establishing a favorable reimbursement climate for metabolic syndrome may be to focus on treating comorbidities

Metabolic Syndrome Reimbursement Forecast: Outlook Remains Cloudy

In the near term, the best prospect for establishing a favorable reimbursement climate for metabolic syndrome may be to focus on treating comorbidities

Public Citizen Meridia petition denied

Abbott's Meridia (sibutramine) will remain on the market after FDA denies Public Citizen's 2002 petition to withdraw the weight-loss drug. In its Aug. 9 FDL-1response, FDA acknowledges some risks associated with Meridia but says they can be addressed by Abbott's recently revised risk management program. The agency also disputes Public Citizen's use of AERS reports to support its argument that the fatality rate associated with Meridia is enough to warrant its withdrawal. Abbott's 9,000-patient long-term safety study (SCOUT) may address the issue; as of April, 8,000 patients had been enrolled (1"The Pink Sheet" June 25, 2001, p. 13)...

Related Content

UsernamePublicRestriction

Register

PS038050

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel